Time to onset and time to resolution of extrapyramidal symptoms in patients with exacerbated schizophrenia treated with 3-monthly vs once-monthly paliperidone palmitate

Objective The aim of this study was to evaluate the safety of 3-monthly paliperidone palmitate (PP3M) vs once-monthly paliperidone palmitate (PP1M) treatment with regard to extrapyramidal symptom (EPS)-related treatment-emergent adverse events (TEAEs) in patients with schizophrenia, previously stabilized on PP1M treatment. Patients and methods Data on overall incidence, time to onset (TTO), and time to resolution (TTR) of EPS-related TEAEs (overall, subclasses such as dyskinesia, dystonia, hyperkinesia, parkinsonism, and tremor) from a randomized double-blind (DB) non-inferiority study were compared between PP3M and PP1M. Subgroup analysis was performed by age (18–25, 26–50, and 50+ years) and final open-label (OL) dose (50/75, 100, and 150 mg eq.). Results Overall incidence of spontaneously reported EPS-related TEAEs decreased from 12.6% (PP1M) in OL phase to 8.3% (PP3M) and 7.4% (PP1M) in the DB phase; overall median TTO and TTR values were comparable between both groups. Among patients with reported EPS-related TEAEs, the median TTO for all EPS-related TEAEs was 17 days (PP1M) in OL phase and 115 days (PP3M) and 98.5 days (PP1M) in DB phase; median TTR was 36.5 days (PP1M) in OL phase and 91 days (PP3M) and 85.5 days (PP1M) in DB phase. No clear dose- or age-related differences in TTO and TTR of EPS-related TEAEs were noted. Conclusion Despite differences in apparent half-life and pharmacokinetic profiles (peak plasma exposure of PP3M formulation is 70% higher than that of PP1M formulation), both PP3M and PP1M formulations exhibited comparable incidence of EPS-related TEAEs, TTO, and TTR in patients with schizophrenia.

[1]  C. Correll,et al.  Long-Acting Injections in Schizophrenia: a 3-Year Update on Randomized Controlled Trials Published January 2016–March 2019 , 2019, Current Psychiatry Reports.

[2]  E. Plan,et al.  Population Pharmacokinetics of a Novel Once-Every 3 Months Intramuscular Formulation of Paliperidone Palmitate in Patients with Schizophrenia , 2017, Clinical Pharmacokinetics.

[3]  B. Carpiniello,et al.  Critical appraisal of 3-monthly paliperidone depot injections in the treatment of schizophrenia , 2016, Drug design, development and therapy.

[4]  S. Gopal,et al.  Pharmacokinetics, safety, and tolerability of paliperidone palmitate 3‐month formulation in patients with schizophrenia: A phase‐1, single‐dose, randomized, open‐label study , 2016, Journal of clinical pharmacology.

[5]  W. Fleischhacker,et al.  Efficacy and Safety of Paliperidone Palmitate 3-Month Formulation for Patients with Schizophrenia: A Randomized, Multicenter, Double-Blind, Noninferiority Study , 2016, The international journal of neuropsychopharmacology.

[6]  J. Stoddard,et al.  Antipsychotic Adherence and Rehospitalization in Schizophrenia Patients Receiving Oral Versus Long-Acting Injectable Antipsychotics Following Hospital Discharge. , 2015, Journal of managed care & specialty pharmacy.

[7]  Yanning Liu,et al.  Efficacy and Safety of the 3-Month Formulation of Paliperidone Palmitate vs Placebo for Relapse Prevention of Schizophrenia: A Randomized Clinical Trial. , 2015, JAMA psychiatry.

[8]  J. Lindenmayer,et al.  Paliperidone palmitate once-monthly reduces risk of relapse of psychotic, depressive, and manic symptoms and maintains functioning in a double-blind, randomized study of schizoaffective disorder. , 2015, The Journal of clinical psychiatry.

[9]  Chang Yoon Kim,et al.  Efficacy, safety, and impact on hospitalizations of paliperidone palmitate in recent-onset schizophrenia , 2015, Neuropsychiatric disease and treatment.

[10]  Yanning Liu,et al.  Incidence and time course of extrapyramidal symptoms with oral and long-acting injectable paliperidone: a posthoc pooled analysis of seven randomized controlled studies , 2013, Neuropsychiatric disease and treatment.

[11]  R. McIntyre,et al.  Treatment-emergent adverse events associated with atypical antipsychotics , 2012, Expert opinion on pharmacotherapy.

[12]  S. Gopal,et al.  A 52-week open-label study of the safety and tolerability of paliperidone palmitate in patients with schizophrenia , 2011, Journal of psychopharmacology.

[13]  I. König,et al.  Risk for antipsychotic-induced extrapyramidal symptoms: influence of family history and genetic susceptibility , 2011, Psychopharmacology.

[14]  J. Lindenmayer,et al.  A Randomized, Placebo-Controlled Study to Assess the Efficacy and Safety of 3 Doses of Paliperidone Palmitate in Adults With Acutely Exacerbated Schizophrenia , 2010, Journal of clinical psychopharmacology.

[15]  S. Gopal,et al.  Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: A randomized, double-blind, placebo-controlled study , 2010, Schizophrenia Research.

[16]  E. Stip,et al.  Substance abuse is associated with increased extrapyramidal symptoms in schizophrenia: A meta-analysis , 2009, Schizophrenia Research.

[17]  A. Vermeulen,et al.  Population Pharmacokinetics of Intramuscular Paliperidone Palmitate in Patients with Schizophrenia , 2009, Clinical pharmacokinetics.

[18]  R. Lencer,et al.  Family history of primary movement disorders as a predictor for neuroleptic-induced extrapyramidal symptoms. , 2004, The British journal of psychiatry : the journal of mental science.

[19]  R. J. Leo,et al.  Atypical Antipsychotic Use in the Treatment of Psychosis in Primary Care. , 2000, Primary care companion to the Journal of clinical psychiatry.

[20]  T. Barnes,et al.  Critical analysis and comparison of the side-effect and safety profiles of the new antipsychotics* , 1999, British Journal of Psychiatry.